Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Global Bronchodilators Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024


 

Available formats:    

StumbleUponEmail

Global Bronchodilators Market: By Drug Class (Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, Combination Drugs), By Route of Administration (Oral, Parenteral, Inhalation), By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Global bronchodilators market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.

 

Market Outline: Bronchodilators Market

Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to lungs.  These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting. Majorly used bronchodilators are include sympathomimetics, phosphodiesterase inhibitors, and anticholinergics among others.

 

Market Dynamics: Bronchodilators Market

Increase in the aging population coupled with rise in prevalence of various lung diseases such as asthma and COPD surge the global bronchodilators market. Moreover, rise in R&D expenditure for the development newer drugs, increase in geriatric population, environmental factors such as air pollution, rise in incidence of respiratory disorders in children, government initiation to improve awareness about the lung diseases, technological advancements of the inhalation devices, and rise in disposable income are propel the global bronchodilators market over the forecast years. However, stringent regulations for the product approval, high cost of products, adverse effects associated with the long term usage of drugs, and rise in awareness programs to prevent the respiratory disorders are restrain the growth of global bronchodilators market.

 

Market Scope: Bronchodilators Market

Bronchodilators market is segmented based on the drug class, route of administration, duration of action, disease type, and distribution channel

Based on the drug class, the market is segmented into the following:

  • Phosphodiesterase Inhibitors
  • Anticholinergics
  • Sympathomimetics
  • Non-Selective Adrenergic Agonists
  • Non-Selective Beta-2 Agonists
  • Selective Beta-2 Agonists
  • Combination Drugs

Based on route of administration, the market is segmented into the following:

  • Oral
  • Parenteral
  • Inhalation

Based on the disease type, the market is segmented into the following:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Regional Analysis:  Bronchodilators Market

Geographically, global bronchodilators market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America bronchodilators market is growing due to rise in R&D for the innovation of newer drugs, rise in prevalence of COPD and asthma, rise in demand for the combination therapies are anticipated to fuel the market. Europe bronchodilators market driven by increase in adoption of newer bronchodilators, rise in disposable income, and rise in awareness about the bronchodilators are spur the market. However, Asia Pacific bronchodilators market has a lucrative growth, attributed to large patient pool in India and China, grow in healthcare expenditure, and launch of newer drugs in Asia Pacific region are bolster the market over the forecast years.

 

Competition Assessment: Bronchodilators Market

Some of the players in the global bronchodilators market include:

  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

 

Notable Market Developments: Bronchodilators Market

  • In April 2016, AstraZeneca received FDA approval for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) used as a bronchodilator in COPD
  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553